IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr

Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23

Virpax reports on progress of Envelta

Envelta is the company’s non-opioid pain product candidate for acute and chronic pain

Glenmark Pharma reports Q3 FY 2022-23 revenue growth of 9.2%; PAT growth of 21.3%

Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY

Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr

The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients

Orchid Pharma reports positive EBIDTA in Q2

The company is focussed on increasing the capacity utilizations while controlling costs

Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr

The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.

Piramal Phamra reports Q2 FY23 consolidated loss at Rs. 37.34 Cr

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal